Evidence map›Paper›PMID 34858891›Full record

ArticleCanadian journal of gastroenterology & hepatology2021

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease.

Panu Wetwittayakhlang, Farah Albader, Petra A Golovics, Gustavo Drügg Hahn, Talat Bessissow, Alain Bitton, Waqqas Afif, Gary Wild, Peter L Lakatos

Open access · goldAbstract read
In one paragraph

Article in Canadian journal of gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. How to Approach the Difficult Perineum in Crohn's Disease.Clinics in colon and rectal surgery · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Panu WetwittayakhlangDivision of Gastroenterology, McGill University Health Center, Montreal, Canada.ORCID 0000-0002-5962-4112
Farah AlbaderDivision of Internal Medicine, McGill University Health Center, Montreal, Canada.ORCID 0000-0003-2657-4558
Petra A GolovicsDivision of Gastroenterology, McGill University Health Center, Montreal, Canada.ORCID 0000-0003-3195-183X
Gustavo Drügg HahnDivision of Gastroenterology, McGill University Health Center, Montreal, Canada.ORCID 0000-0003-1963-7848
Talat BessissowDivision of Gastroenterology, McGill University Health Center, Montreal, Canada.ORCID 0000-0003-2610-1910
Alain BittonDivision of Gastroenterology, McGill University Health Center, Montreal, Canada.ORCID 0000-0001-7214-1978
Waqqas AfifDivision of Gastroenterology, McGill University Health Center, Montreal, Canada.ORCID 0000-0001-6869-0982
Gary WildDivision of Gastroenterology, McGill University Health Center, Montreal, Canada.ORCID 0000-0002-9625-3437
Peter L LakatosDivision of Gastroenterology, McGill University Health Center, Montreal, Canada.ORCID 0000-0002-3948-6488
McGill University Health Centre · CAPrince of Songkla University · THSemmelweis University · HUUniversidade Federal do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The impact of COVID-19 has been of great concern in patients with inflammatory bowel disease (IBD) worldwide, including an increased risk of severe outcomes and/or possible flare of IBD. This study aims to evaluate prevalence, outcomes, the impact of COVID-19 in patients with IBD, and risk factors associated with severe COVID-19 or flare of IBD activity. Methods: A consecutive cohort of IBD patients who were diagnosed with COVID-19 infection and followed up at the McGill University Health Care Centre was obtained between March 1, 2020, and April 30, 2021. Demographics, comorbidities, IBD (type, treatments, pre- and post-COVID-19 clinical activity, biomarkers, and endoscopic activity), and COVID-19-related outcomes (pneumonia, hospitalization, death, and flare of IBD disease) were analyzed. Results: A cohort of 3,516 IBD patients was included. 82 patients (2.3%) were diagnosed with COVID-19 infection (median age: 39.0 (IQR 27.8-48.0), 77% with Crohn's disease, 50% were female). The prevalence of COVID-19 infection in IBD patients was significantly lower compared to the general population in Canada and Quebec (3.5% versus 4.3%, Conclusion: The prevalence of COVID-19 infection among patients with IBD was lower than that in the general population in Canada. Severe COVID-19, mortality, and flare of IBD were relatively rare, while a large proportion of patients received COVID-19 vaccination. Older age, comorbidities, active IBD disease, and systemic corticosteroid, but not immunosuppressive or biological therapy, were associated with severe COVID-19 infection.

Indexed as

COVID-19Crohn DiseaseInflammatory Bowel DiseasesAdultAgedCOVID-19 VaccinesFemaleHumansMiddle AgedSARS-CoV-2COVID-19 Vaccines

Identifiers

PMID34858891
PMCPMC8632463
OpenAlexW3215130509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.